Key result
Intravenous morphine delayed the time to adequate platelet inhibition after prasugrel administration compared to saline.
Why the study?
Does intravenous morphine delay the onset of action of prasugrel in aspirin-treated patients with a prior history of STEMI?
RCT (n=11)
crossover
Does intravenous morphine delay the onset of action of prasugrel in aspirin-treated patients with a prior history of STEMI?
Prior administration of intravenous morphine significantly delays the onset of action of prasugrel, suggesting that intravenous antiplatelet drugs may be necessary to reduce the risk of acute stent thrombosis in morphine-treated STEMI patients undergoing PPCI.
Answers are grounded in this paper and cite their sources.
Morphine may delay prasugrel onset in prior-STEMI patients; leaves open need for bridging strategies in PPCI.
Delays in the onset of action of prasugrel during primary percutaneous coronary intervention (PPCI) have been reported and could be related to the effects of morphine on gastric emptying and subsequent intestinal absorption. The study objective was to determine whether morphine delays the onset of action of prasugrel in patients with a prior history of ST-elevation myocardial infarction (STEMI) treated with PPCI. This was a crossover study of 11 aspirin-treated patients with prior history of STEMI treated with PPCI, for which prasugrel and morphine had been previously administered. Patients were randomised to receive either morphine (5 mg) or saline intravenously followed by 60 mg prasugrel. Blood samples were collected before randomised treatment and over 24 hours after prasugrel administration. The inhibitory effects of prasugrel on platelets were determined using the VerifyNow P2Y12 assay and light transmission aggregometry. Plasma levels of prasugrel and prasugrel active metabolite were measured. Platelet reactivity determined by VerifyNow PRU, VerifyNow % Inhibition and LTA was significantly higher at 30-120 minutes (min) when morphine had been co-administered compared to when saline had been co-administered. Morphine, compared to saline, significantly delayed adequate platelet inhibition after prasugrel administration (158 vs 68 min; p = 0.006). Patients with delayed onset of platelet inhibition also had evidence of delayed absorption of prasugrel. In conclusion, prior administration of intravenous morphine significantly delays the onset of action of prasugrel. Intravenous drugs may be necessary to reduce the risk of acute stent thrombosis in morphine-treated STEMI patients undergoing PPCI.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2016) conducted an RCT in prior history of ST-elevation myocardial infarction (STEMI) (n=11). Morphine vs. Saline intravenously followed by 60 mg prasugrel was evaluated on Time to adequate platelet inhibition (p=0.006). Intravenous morphine delayed the time to adequate platelet inhibition after prasugrel administration compared to saline.
Synapse has enriched 10 related papers. Consider them for comparative context: